Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial.

Kolotkin RL, Jeppesen OK, Baker-Knight J, Lee SY, Tokita A, Kadowaki T

Clinical obesity11 Mar 2023Cited by 12 (Europe PMC)

PMID36905345DOI10.1111/cob.12589PepBankPUB-36905345

Publisher page PubMedAsk about this study

Summary

We assessed the effect of semaglutide 2.4 and 1.7 mg versus placebo on weight-related quality of life (WRQOL) and health-related quality of life (HRQOL) in the STEP 6 trial. Adults from East Asia (body mass index [BMI] ≥27.0 kg/m² with ≥2 weight-related comorbidities, or ≥35.0 kg/m² with ≥1 weight-related comorbidity) were randomized 4:1:2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo, or semaglutide 1.7 mg or placebo, plus lifestyle intervention for 68 weeks. WRQOL and HRQOL were assessed from baseline to Week 68 using the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) and the 36-Item-Short-Form-Survey-version-2.0 acute (SF-36v2), with changes in scores by categories of baseline BMI (</≥30 and ≥35 kg/m² ) also assessed. In total, 401 participants (mean body weight 87.5 kg, aged 51 years, BMI 31.9 kg/m² , waist circumference 103.2 cm) were included. From baseline to Week 68, the IWQOL-Lite-CT Psychosocial and Total scores were significantly improved with semaglutide 2.4 and 1.7 mg versus placebo. For Physical score, effects were only in favour of semaglutide 2.4 mg versus placebo. In the SF-36v2, Physical Functioning was significantly improved with semaglutide 2.4 mg versus placebo, but no beneficial effects favouring either semaglutide treatment arms versus placebo were seen in the other SF-36v2 domains. Benefits favouring semaglutide 2.4 mg versus placebo were also observed in subgroups with higher BMIs for IWQOL-Lite-CT and SF-36v2 Physical Functioning scores. Treatment with semaglutide 2.4 mg improved aspects of WRQOL and HRQOL in people from East Asia with overweight/obesity.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In East Asian adults with overweight or obesity, semaglutide 2.4 mg improved the IWQOL-Lite-CT Psychosocial score versus placebo at week 68.
In plain wordsIn East Asian adults with overweight or obesity, semaglutide 2.4 mg improved weight-related psychosocial quality of life more than placebo.
Peptide
Semaglutide
Outcome
IncreaseIWQOL-Lite-CT Psychosocial score, semaglutide 2.4 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Source sentences
Summary
From baseline to Week 68, the IWQOL-Lite-CT Psychosocial and Total scores were significantly improved with semaglutide 2.4 and 1.7 mg versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults from East Asia (body mass index [BMI] ≥27.0 kg/m² with ≥2 weight-related comorbidities, or ≥35.0 kg/m² with ≥1 weight-related comorbidity) were randomized 4:1:2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo, or semaglutide 1.7 mg or placebo, plus lifestyle intervention for 68 weeks.
Show in the study text Report a problemFND-3690534501
02HumanRandomized controlled trialEfficacy outcome
In East Asian adults with overweight or obesity, semaglutide 1.7 mg improved the IWQOL-Lite-CT Psychosocial score versus placebo at week 68.
In plain wordsIn East Asian adults with overweight or obesity, semaglutide 1.7 mg improved weight-related psychosocial quality of life more than placebo.
Peptide
Semaglutide
Outcome
IncreaseIWQOL-Lite-CT Psychosocial score, semaglutide 1.7 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
1.7 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Source sentences
Summary
From baseline to Week 68, the IWQOL-Lite-CT Psychosocial and Total scores were significantly improved with semaglutide 2.4 and 1.7 mg versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults from East Asia (body mass index [BMI] ≥27.0 kg/m² with ≥2 weight-related comorbidities, or ≥35.0 kg/m² with ≥1 weight-related comorbidity) were randomized 4:1:2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo, or semaglutide 1.7 mg or placebo, plus lifestyle intervention for 68 weeks.
Show in the study text Report a problemFND-3690534502
03HumanRandomized controlled trialEfficacy outcome
In East Asian adults with overweight or obesity, semaglutide 2.4 mg improved the IWQOL-Lite-CT Total score versus placebo at week 68.
In plain wordsIn East Asian adults with overweight or obesity, semaglutide 2.4 mg improved overall weight-related quality of life more than placebo.
Peptide
Semaglutide
Outcome
IncreaseIWQOL-Lite-CT Total score, semaglutide 2.4 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Source sentences
Summary
From baseline to Week 68, the IWQOL-Lite-CT Psychosocial and Total scores were significantly improved with semaglutide 2.4 and 1.7 mg versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults from East Asia (body mass index [BMI] ≥27.0 kg/m² with ≥2 weight-related comorbidities, or ≥35.0 kg/m² with ≥1 weight-related comorbidity) were randomized 4:1:2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo, or semaglutide 1.7 mg or placebo, plus lifestyle intervention for 68 weeks.
Show in the study text Report a problemFND-3690534503
04HumanRandomized controlled trialEfficacy outcome
In East Asian adults with overweight or obesity, semaglutide 1.7 mg improved the IWQOL-Lite-CT Total score versus placebo at week 68.
In plain wordsIn East Asian adults with overweight or obesity, semaglutide 1.7 mg improved overall weight-related quality of life more than placebo.
Peptide
Semaglutide
Outcome
IncreaseIWQOL-Lite-CT Total score, semaglutide 1.7 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
1.7 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Source sentences
Summary
From baseline to Week 68, the IWQOL-Lite-CT Psychosocial and Total scores were significantly improved with semaglutide 2.4 and 1.7 mg versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults from East Asia (body mass index [BMI] ≥27.0 kg/m² with ≥2 weight-related comorbidities, or ≥35.0 kg/m² with ≥1 weight-related comorbidity) were randomized 4:1:2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo, or semaglutide 1.7 mg or placebo, plus lifestyle intervention for 68 weeks.
Show in the study text Report a problemFND-3690534504
05HumanRandomized controlled trialEfficacy outcome
In East Asian adults with overweight or obesity, semaglutide 2.4 mg improved the IWQOL-Lite-CT Physical score versus placebo at week 68.
In plain wordsIn East Asian adults with overweight or obesity, semaglutide 2.4 mg improved weight-related physical quality of life more than placebo.
Peptide
Semaglutide
Outcome
IncreaseIWQOL-Lite-CT Physical score, semaglutide 2.4 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Source sentences
Summary
For Physical score, effects were only in favour of semaglutide 2.4 mg versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults from East Asia (body mass index [BMI] ≥27.0 kg/m² with ≥2 weight-related comorbidities, or ≥35.0 kg/m² with ≥1 weight-related comorbidity) were randomized 4:1:2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo, or semaglutide 1.7 mg or placebo, plus lifestyle intervention for 68 weeks.
Show in the study text Report a problemFND-3690534505
06HumanRandomized controlled trialEfficacy outcome
In East Asian adults with overweight or obesity, semaglutide 1.7 mg did not improve the IWQOL-Lite-CT Physical score versus placebo; effects favoured only the 2.4 mg dose.
In plain wordsIn East Asian adults with overweight or obesity, semaglutide 1.7 mg did not improve weight-related physical quality of life compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeIWQOL-Lite-CT Physical score, semaglutide 1.7 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
1.7 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Source sentences
Summary
For Physical score, effects were only in favour of semaglutide 2.4 mg versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults from East Asia (body mass index [BMI] ≥27.0 kg/m² with ≥2 weight-related comorbidities, or ≥35.0 kg/m² with ≥1 weight-related comorbidity) were randomized 4:1:2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo, or semaglutide 1.7 mg or placebo, plus lifestyle intervention for 68 weeks.
Show in the study text Report a problemFND-3690534506
07HumanRandomized controlled trialEfficacy outcome
In East Asian adults with overweight or obesity, semaglutide 2.4 mg significantly improved SF-36v2 Physical Functioning versus placebo.
In plain wordsIn East Asian adults with overweight or obesity, semaglutide 2.4 mg improved physical functioning more than placebo.
Peptide
Semaglutide
Outcome
IncreaseSF-36v2 Physical Functioning, semaglutide 2.4 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Source sentences
Summary
Physical Functioning was significantly improved with semaglutide 2.4 mg versus placebo,
1 context sentence(design, population, supporting numbers)
Summary · context
Adults from East Asia (body mass index [BMI] ≥27.0 kg/m² with ≥2 weight-related comorbidities, or ≥35.0 kg/m² with ≥1 weight-related comorbidity) were randomized 4:1:2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo, or semaglutide 1.7 mg or placebo, plus lifestyle intervention for 68 weeks.
Show in the study text Report a problemFND-3690534507
08HumanRandomized controlled trialEfficacy outcome
In East Asian adults with overweight or obesity, semaglutide 2.4 mg showed no beneficial effect versus placebo in the other SF-36v2 domains.
In plain wordsIn East Asian adults with overweight or obesity, semaglutide 2.4 mg did not improve the other SF-36 quality-of-life areas compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeSF-36v2 other domains, semaglutide 2.4 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Source sentences
Summary
but no beneficial effects favouring either semaglutide treatment arms versus placebo were seen in the other SF-36v2 domains.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults from East Asia (body mass index [BMI] ≥27.0 kg/m² with ≥2 weight-related comorbidities, or ≥35.0 kg/m² with ≥1 weight-related comorbidity) were randomized 4:1:2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo, or semaglutide 1.7 mg or placebo, plus lifestyle intervention for 68 weeks.
Show in the study text Report a problemFND-3690534508
09HumanRandomized controlled trialEfficacy outcome
In East Asian adults with overweight or obesity, semaglutide 1.7 mg showed no beneficial effect versus placebo in the other SF-36v2 domains.
In plain wordsIn East Asian adults with overweight or obesity, semaglutide 1.7 mg did not improve the other SF-36 quality-of-life areas compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeSF-36v2 other domains, semaglutide 1.7 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
1.7 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Source sentences
Summary
but no beneficial effects favouring either semaglutide treatment arms versus placebo were seen in the other SF-36v2 domains.
1 context sentence(design, population, supporting numbers)
Summary · context
Adults from East Asia (body mass index [BMI] ≥27.0 kg/m² with ≥2 weight-related comorbidities, or ≥35.0 kg/m² with ≥1 weight-related comorbidity) were randomized 4:1:2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo, or semaglutide 1.7 mg or placebo, plus lifestyle intervention for 68 weeks.
Show in the study text Report a problemFND-3690534509
10HumanRandomized controlled trialEfficacy outcome
In East Asian adults with overweight or obesity and higher BMIs, semaglutide 2.4 mg improved IWQOL-Lite-CT and SF-36v2 Physical Functioning scores versus placebo.
In plain wordsIn East Asian adults with overweight or obesity and higher BMIs, semaglutide 2.4 mg improved these quality-of-life scores more than placebo.
Peptide
Semaglutide
Outcome
IncreaseIWQOL-Lite-CT and SF-36v2 Physical Functioning in higher BMI subgroups, semaglutide 2.4 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Whole body
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Source sentences
Summary
Benefits favouring semaglutide 2.4 mg versus placebo were also observed in subgroups with higher BMIs for IWQOL-Lite-CT and SF-36v2 Physical Functioning scores.
2 context sentences(design, population, supporting numbers)
Summary · context
WRQOL and HRQOL were assessed from baseline to Week 68 using the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) and the 36-Item-Short-Form-Survey-version-2.0 acute (SF-36v2), with changes in scores by categories of baseline BMI (</≥30 and ≥35 kg/m² ) also assessed.
Summary · context
Adults from East Asia (body mass index [BMI] ≥27.0 kg/m² with ≥2 weight-related comorbidities, or ≥35.0 kg/m² with ≥1 weight-related comorbidity) were randomized 4:1:2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo, or semaglutide 1.7 mg or placebo, plus lifestyle intervention for 68 weeks.
Show in the study text Report a problemFND-3690534510

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.